Kenneth P. Olive

This study identifies PHGDH as a driver of PDAC progression by maintaining glutamine metabolism and mTOR signaling, revealing a therapeutic vulnerability to glutamine antagonism in PHGDH-deficient tumors.

This paper shows that combining HDAC and eIF4A inhibitors effectively treats pancreatic cancer by inducing epigenetic reprogramming and metabolic stress in preclinical models.

This study identifies NTN1/NEO1 as a key driver of pancreatic tumorigenesis and metastasis by promoting cancer stemness, EMT, and nerve innervation.

This study engineers a probiotic bacteria to selectively target pancreatic cancer, improving survival and modulating the tumor microenvironment.

This study evaluates the therapeutic potential of RMC-7977, a broad-spectrum RAS inhibitor, in pancreatic ductal adenocarcinoma models, showing strong anti-tumor effects with minimal impact on normal tissues.

This study shows that combining gemcitabine with CXCR4 inhibitors and anti-PD1 therapy improves immune response and survival in pancreatic cancer models.

The paper validates an RNA-based platform for predicting drug sensitivity in treatment-resistant cancers using patient-derived xenograft models and multi-protein therapies.

The paper develops an algorithm to deconvolve bulk tumor gene expression data and identifies consistent functional subtypes in pancreatic cancer epithelium and stroma.